About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 4369 record(s)
Req # A-2023-000106
Adverse Drug Reactions (ADRs). Report numbers: E2B_05651003, E2B_03722288, E2B_03692076, E2B_05075695, E2B_05638768, E2B_05957614, E2B_04794794, E2B_01281932, E2B_04813234, E2B_04528744.Organization: Health Canada
April 2024
Req # A-2023-000782
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-075176-860.Organization: Health Canada
April 2024
Req # A-2023-000834
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105345-217.Organization: Health Canada
April 2024
Req # A-2023-001018
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107751-725.Organization: Health Canada
April 2024
Req # A-2023-001019
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107996-10.Organization: Health Canada
April 2024
Req # A-2023-001197
Adverse Drug Reactions (ADRs) for Patiromer. Report numbers: E2B_06597912, E2B_06621747,E2B_06621748, E2B_06635757, E2B_06649755, E2B_06686722, E2B_06709717. ADRs for Brexpiprazole. Report numbers: E2B_06679153, E2B_06690064. ADR for Rexulti and…Organization: Health Canada
April 2024
Req # A-2023-001199
Adverse Drug Reactions (ADRs) for Tavneos. Report numbers: E2B_06591082, E2B_06617481, E2B_06623216, E2B_06634823, E2B_06639043, E2B_06641713, E2B_06672043, E2B_06685595, E2B_06691805. ADR for . Report number: 001055046.Organization: Health Canada
April 2024
Req # A-2023-001205
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_06666868, E2B_06659902, E2B_06697588, E2B_06702227, E2B_06662559,E2B_06707974. ADR for Dexilant. Report number: 001069005. ADR for Entyvio. Report number: E2B_06698466. ADR for…Organization: Health Canada
April 2024
Req # A-2023-001232
Adverse Drug Reactions (ADRs). Report numbers: 001063643, E2B_06694721, E2B_06676239.Organization: Health Canada
April 2024
Req # A-2023-001247
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-110762-550.Organization: Health Canada
April 2024